Jefferies Upgrades Pfizer to Buy, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Akash Tewari has upgraded Pfizer (NYSE:PFE) from Hold to Buy and raised the price target from $38 to $39.
October 16, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer has been upgraded from Hold to Buy by Jefferies analyst Akash Tewari, with a raised price target from $38 to $39.
The upgrade from Hold to Buy indicates a positive outlook for Pfizer's stock. The raised price target from $38 to $39 suggests that the analyst believes the stock has potential for growth in the short term. This could lead to increased investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100